Gastric cancer is one of the most common types of cancer in the world, usually diagnosed at
an advanced stage. Despite the advances in specific anticancer agents' development, the …

Amplification of the human epidermal growth factor receptor 2 (HER2) gene and
overexpression of the HER2 protein is found in 15%-20% of patients with gastric and …

Gastric cancer (GC) is one of the leading causes of cancer death worldwide. Despite
significant improvement in understanding disease biology and recent improvements in …

Identification of the importance of human epidermal growth factor receptor-2 (HER2) status,
biomarker testing and the development of anti-HER2 treatments have changed the …

Opinion Statement The majority of patients with esophagogastric cancer present with
advanced disease, which is incurable. Systemic chemotherapy can lead to a decrease in …

Recent advances in molecular targeted therapies, including targeting human epidermal
growth factor receptor 2 (HER2), had a major forward step in the therapy for gastric cancer …

Despite recent advances in the treatment of gastric cancer, mortality related to this disease is
still substantial. Surgery and chemotherapy represent the cornerstones of patient …

Opinion statement Gastric and gastroesophageal junction (GEJ) cancers represent the third
leading cause of malignancy-associated death worldwide. Approximately 15–20% of these …

The discovery of human epidermal growth factor receptor 2 (HER2) overexpression in 15–
20% of gastric adenocarcinomas has been a key advance in the global care of this disease …

Treatment options for patients with HER2-positive advanced gastric cancer are limited, and
the prognosis for these patients is poor. Pembrolizumab has demonstrated promising …